106,99 €
inkl. MwSt.
Sofort per Download lieferbar
  • Format: PDF

Immunology and Rheumatology in Questions, 2nd Edition addresses through short and concise questions-and-answers (Q&As) on one hand all major aspects of basic clinical and laboratory immunology necessary for understanding underlying immunological mechanisms of autoimmune rheumatic diseases. The majority however of Q&As in this book presents in a laconic way definitions, pathogenetic aspects, clinical and laboratory manifestations, differential diagnosis and the management of all categories of rheumatic diseases including systemic autoimmune, autoinflammatory, metabolic and degenerative.…mehr

Produktbeschreibung
Immunology and Rheumatology in Questions, 2nd Edition addresses through short and concise questions-and-answers (Q&As) on one hand all major aspects of basic clinical and laboratory immunology necessary for understanding underlying immunological mechanisms of autoimmune rheumatic diseases. The majority however of Q&As in this book presents in a laconic way definitions, pathogenetic aspects, clinical and laboratory manifestations, differential diagnosis and the management of all categories of rheumatic diseases including systemic autoimmune, autoinflammatory, metabolic and degenerative. Furthermore, in separate sections of this manual Q&As addressing rheumatic manifestations from other organ systems are included. Finally, a chapter is devoted to treatment of rheumatic diseases analyzing indications and side-effects of different therapeutic modalities with illustrations and diagrams utilized throughout the book to present the information in a clear and schematic way.

In this fully revised second edition, more than 120 new Q&As have been added and the answers to more than 90 Q&As has been modified after having critically incorporated all new knowledge generated in the past three years in the field of rheumatology, in an effort to bridge classical and current evidence-based knowledge and to present didactic and credible information. This book is valuable to test and acquire knowledge not only for rheumatologists but for every specialist in internal medicine, family practice, physical/rehabilitation medicine and orthopedic surgery.

Autorenporträt
Haralampos M. Moutsopoulos, MD, FACP, FRCP is an Emeritus Professor of the Medical School, University of Athens, Greece and active Member of Athens Academy holding the chair of Medical sciences-Immunology. His research has contributed to current understanding of the clinical aspects, pathogenesis and therapy of autoimmune rheumatic disorders. He is considered a world authority on Sjögren's syndrome (autoimmune Epithelitis). His scientific work is extensively cited (>51000, h factor >110) and he has been awarded with numerous national and international awards.

Evangelia Zampeli, MD, PhD is a Consultant Rheumatologist in Bioclinic General Hospital of Athens and Associate Member of the Institute for Autoimmune Systemic and Neurological Disorders, Athens, Greece. She has obtained her PhD on Immunopharmacology and continues her research which is concentrated on clinical and immunologic aspects of systemic autoimmune diseases.

Panayiotis G. Vlachoyiannopoulos, MD, PhD is Professor of Medicine and Immunology at the University of Athens, School of Medicine. He has studied the clinical presentation, epidemiology and pathogenic aspects of systemic autoimmune connective tissue diseases using as a disease model of the antiphospholipid syndrome. He has written extensively on these topics and has published 126 peer reviewed articles.

Jacques-Olivier Pers, DDS, PhD is Professor of Immunology and Director of the INSERM research team UMR1227 “B cells and autoimmunity” at the University of Brest, Laboratory of Immunology, France. His research focuses on immunopathology and immunotherapy dedicated to the study of normal and pathological B cells. He has studied different disease models of autoimmune diseases (Sjögren’s syndrome, systemic lupus erythematosus, rheumatoid arthritis), lymphoproliferative disorders (chronic lymphocytic leukemia), and kidney graft rejection from upstream approaches (epigenetics and autoimmunity, the genetic control of BAFF, calcium signaling, regulatory B cells) to downstream approaches (multicenter clinical trials, IVIg, patents).